Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.28, $0.03 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.52 billion.

Guidance for Remainder of 2020:

On March 30, 2020, the company withdrew its sales and EPS guidance for the full year 2020, originally provided on February 5, 2020. Due to the uncertain scope and duration of the COVID-19 pandemic, timing of global recovery and economic normalization, the company is unable to estimate the overall impacts on its operations and financial results for the remainder of 2020.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.